Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 4 PART I, 1998, Pages 1187-1194

  Dahlén, Barbro ^a   Nizankowska, Ewa ^b   Szczeklik, Andrew ^b   Zetterström, Olle ^b   Bochenek, Grazyna ^b   Kumlin, Maria ^b   Mastalerz, Lucyna ^b   Pinis, Grazyna ^b   Swanson, Linda J ^b   Boodhoo, Terry I ^b   Wright, Stephen ^b   Dubé, Louise M ^b   Dahlén, Sven Erik ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BECLOMETASONE; BUDESONIDE; CROMOGLYCATE DISODIUM; THEOPHYLLINE; ZILEUTON;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ASPIRIN; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HISTAMINE; HUMANS; HYDROXYUREA; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE;

EID: 19244370387     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.4.9707089     Document Type: Article

References (21)

1. Szczeklik, A. 1997. Mechanism of aspirin-induced asthma. Allergy 52:613-619.
2. Stevenson, D. D., and R. A. Simon. 1988. Aspirin sensitivity: respiratory and cutaneous manifestations. In E. Middleton, Jr., C. E. Reed, E. F. Ellis, N. F. Adkinson, and J. W. Yunginger, editors. Allergy, Principles and Practice. Mosby, St. Louis. 1537-1554.
3. Szczeklik, A., R. J. Gryglewski, and G. Czerniawska-Mysik. 1975. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. B.M.J. 1:67-69.
4. Holgate, S. T., and S.-E. Dahlén. 1997. From SRS-A to Leukotrienes: The Dawning of a New Treatment. Blackwell Science Ltd, Oxford.
5. 4 causes granulocyte infiltration into asthmatic airways. Lancet 341:989-990.
6. 4 and methacholine on sputum cell differentials in asthma. Am. J. Respir. Crit. Care Med. 155:1247-1253.
7. Munoz, N. M., I. Douglas, D. Mayer, A. Herrnreiter, X. Zhu, and A. R. Leff. 1997. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am. J. Respir. Crit. Care Med. 155:1398-1403.
8. Dahlén, B., M. Kumlin, D. J. Margolskee, C. Larsson, H. Blomqvist, V. C. Williams, O. Zetterström, and S.-E. Dahlén. 1993. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur. Respir. J. 6:1018-1026.
9. Yamamoto, H., M. Nagata, K. Kuramitsu, K. Tabe, H. Kiuchi, Y. Sakamoto, K. Yamamoto, and Y. Dohi. 1994. Inhibition of analgesic-induced asthma by the leukotriene receptor antagonist ONO-1078. Am. J. Respir. Crit. Care Med. 150:254-257.
10. Christie, P. E., C. M. Smith, and T. H. Lee. 1991. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am. Rev. Respir. Dis. 144:957-958.
11. Israel, E., A. R. Fischer, M. A. Rosenberg, C. M. Lilly, J. C. Callery, J. Shapiro, J. Cohn, P. Rubin, and J. M. Drazen. 1993. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. 148:1447-1451.
12. Nasser, S. M., G. S. Bell, S. Foster, K. E. Spruce, R. MacMillan, A. J. Williams, T. H. Lee, and J. P. Arm. 1994. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 49:749-756.
13. 4 concentrations increase after ASA challenge in ASA-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143:1025-1029.
14. 4, and histamine in asthmatics. Am. Rev. Respir. Dis. 146:96-103.
15. 4 in subjects with ASA-induced asthma. Am. Rev. Respir. Dis. 140:148-153.
16. Dahlén, B., D. J. Margolskee, O. Zetterström, and S.-E. Dahlén. 1993. Effect of the leukotriene-antagonist MK-0679 on baseline pulmonary function in aspirin-sensitive asthmatics. Thorax 48:1205-1210.
17. McGill, K. A., and W. W. Busse. 1996. Zileuton. Lancet 348:519-524.
18. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretions in humans. Clin. Allergy 16:289-297.
19. 4 in grass pollen-induced rhinitis. Am. Rev. Respir. Dis. 136:357-362.
20. 4 in human urine. Clin. Exp. Allergy 25:467-479.
21. Rubin, P., L. Dubé, R. Braeckman, L. Swanson, R. Hansen, D. Albert, and G. Carter. 1991. Pharmacokinetics, safety and ability to diminish leukotriene synthesis by zileuton, an inhibitor of the 5-lipoxygenase. Agents Actions 35(Suppl.):103-116.